Diversify Advisory Services LLC Purchases New Shares in Medpace Holdings, Inc. (NASDAQ:MEDP)

Diversify Advisory Services LLC purchased a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 1,641 shares of the company’s stock, valued at approximately $653,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of MEDP. RiverPark Advisors LLC purchased a new stake in Medpace in the fourth quarter worth $26,000. Contravisory Investment Management Inc. purchased a new stake in Medpace in the fourth quarter worth $26,000. Rise Advisors LLC purchased a new stake in Medpace in the first quarter worth $27,000. Mather Group LLC. purchased a new stake in Medpace in the first quarter worth $28,000. Finally, GAMMA Investing LLC purchased a new stake in Medpace in the fourth quarter worth $30,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Buying and Selling at Medpace

In other Medpace news, CEO August J. Troendle sold 4,782 shares of the stock in a transaction dated Wednesday, May 8th. The stock was sold at an average price of $400.58, for a total value of $1,915,573.56. Following the completion of the sale, the chief executive officer now directly owns 716,197 shares in the company, valued at $286,894,194.26. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other Medpace news, CEO August J. Troendle sold 4,782 shares of the stock in a transaction dated Wednesday, May 8th. The stock was sold at an average price of $400.58, for a total value of $1,915,573.56. Following the completion of the sale, the chief executive officer now directly owns 716,197 shares in the company, valued at $286,894,194.26. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO August J. Troendle sold 15,102 shares of the stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $400.69, for a total value of $6,051,220.38. Following the completion of the sale, the chief executive officer now owns 791,541 shares of the company’s stock, valued at $317,162,563.29. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 29,621 shares of company stock worth $11,816,852. 20.30% of the stock is owned by insiders.

Analysts Set New Price Targets

MEDP has been the topic of a number of recent analyst reports. Mizuho initiated coverage on Medpace in a research note on Tuesday, May 28th. They issued a “buy” rating and a $435.00 target price on the stock. Robert W. Baird increased their price target on Medpace from $446.00 to $454.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 24th. Guggenheim increased their price target on Medpace from $453.00 to $464.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Deutsche Bank Aktiengesellschaft assumed coverage on Medpace in a research report on Monday, March 18th. They set a “hold” rating and a $395.00 price target on the stock. Finally, Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and increased their price target for the stock from $340.00 to $450.00 in a research report on Tuesday, April 23rd. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $443.14.

Medpace Stock Performance

MEDP stock traded down $0.67 during trading on Friday, reaching $402.40. 115,524 shares of the company traded hands, compared to its average volume of 184,461. Medpace Holdings, Inc. has a 12 month low of $227.21 and a 12 month high of $437.39. The business has a 50 day simple moving average of $398.20 and a 200 day simple moving average of $370.72. The company has a market capitalization of $12.47 billion, a price-to-earnings ratio of 41.02, a price-to-earnings-growth ratio of 1.99 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, beating analysts’ consensus estimates of $2.45 by $0.75. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The company had revenue of $511.00 million for the quarter, compared to the consensus estimate of $512.39 million. During the same quarter last year, the company earned $2.27 earnings per share. The firm’s revenue for the quarter was up 17.7% compared to the same quarter last year. As a group, research analysts forecast that Medpace Holdings, Inc. will post 11.29 EPS for the current year.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.